Navigation Links
Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum
Date:4/17/2014

NEW YORK (17 April 2014) Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study also provides the first data that the gel is effective against multiple strains of HIV, and has a window of efficacy in the vagina against all three viruses of at least eight hours prior to exposure. A Phase 1 safety trial of the gel is set to begin enrollment in May 2014.

These findings were published today in PLOS ONE in an article entitled "A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV."

The gel, known as MZC, contains two potent antiviral agents: MIV-150 and zinc acetate. MIV-150 is an enzyme inhibitor that prevents HIV-infected cells from producing new virus, and zinc acetate is an antiviral agent with known activity against HIV and HSV-2. These compounds are mixed in a base of carrageenan, a compound derived from seaweed that has also been shown to have potent activity against HPV. Infection with HSV-2 or HPV is associated with increased risk of HIV infection. Microbicides that target HIV, HSV-2, and HPV may more effectively limit HIV transmission than those that target HIV alone.

In this study, Council scientists and their partners used macaque and mouse models to examine whether MZC gel could prevent the vaginal and rectal transmission of SHIV-RT, HSV-2, and HPV. SHIV-RT is a human/simian immunodeficiency chimeric virus combining the HIV reverse transcriptase (RT) within SIV (the monkey version of HIV). MIV-150 and zinc acetate inhibit HIV-RT via different mechanisms of action. Preclinical testing in animals is required by the FDA and is important to ensure the highest level of safety and to build the evidence base for potential efficacy in humans.

"It is the versatility of MZC that makes it a desirable microbicide candidate," said Jos A. Fernndez Romero, a scientist at the Population Council and corresponding author of the paper. "It is effective against multiple viruses, can be used in both the vagina and the rectum, and retains its efficacy in the vagina over an extended period of time. In addition to the gel, we are also exploring sustained-release intravaginal rings and on-demand film-based delivery systems for MZC. There is a growing demand for microbicides that prevent multiple STIs, and we are committed to ensuring that women and men have options when choosing what works most effectively for their own protection."


'/>"/>

Contact: Melanie Boyer
mboyer@popcouncil.org
202-237-9404
Population Council
Source:Eurekalert

Related medicine news :

1. Researchers develop a new cell and animal model of inflammatory breast cancer
2. FDA Seeks to Limit Antibiotics in Animal Feed
3. Animals More Interesting to Kids Than Toys, Study Shows
4. Raucous Music May Tap Into Your Inner Animal
5. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
6. Woodbridge Animal Hospital Unleashes New Pet Care Website
7. Chicago Dog Bite Injury Lawyers Advise Dog Owners To Get Control of Their Animals, Or Be Prepared To Pay Up
8. New technique could reduce number of animals needed to test chemical safety
9. Potential treatment target identified in an animal model of pancreatic cancer
10. New animal model may lead to treatments for common liver disease
11. Lab-engineered muscle implants restore function in animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today announced ... Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at the ... for the UVA Health System, brings 30 years of highly relevant experience to his ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced ... its existing adherence automation lines. The ATP® Mini and InspectRx® Mini ... TCG’s standard products, but at a size and price point that can help ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology: